Rehabilitation Proceedings and Delisting Risk, Severely Deteriorated Financial Structure
-
Rehabilitation proceedings commenced (Sep 2025) and rehabilitation plan approved (May 2026); credit rating downgraded to D (default)
-
KOSDAQ delisting decision (Apr 2026) followed by injunction application to suspend effect
-
Consolidated capital impairment: total equity –25.2B KRW, total liabilities 71.5B KRW, current liabilities exceed current assets by 44.3B KRW
-
Q1 2026 operating loss 1.57B KRW, net loss 2.29B KRW, sales down 53% YoY
-
Of cash equivalents 3.7B KRW, 4.4B KRW are restricted due to seizure/pledge
-
No dividend or share buyback/cancellation plans
KOSDAQ Filing Information
-
Filing: Quarterly Report (2026.03)
-
Company: UNION KOREA PHARM (080720)
-
Submission: UNION KOREA PHARM CO.,Ltd
-
Receipt: 05-14-2026